COMMUNIQUÉS West-GlobeNewswire

Hydreight Technologies to Present at Maxim Group’s 2025 Virtual Tech Conference & the CEM Bermuda Capital Event
14/05/2025
VANCOUVER, British Columbia and LAS VEGAS, May 14, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform [...]
Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models
14/05/2025
Global Chronic Ocular Pain Market Valued at US$ 7.2 Billion in 2023 and Is Projected To Reach US$ 12.44 Billion by 2032 at a CAGR of 6.6% During Forecast Period 2024–2032 FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE [...]
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
14/05/2025
Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its [...]
Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing
14/05/2025
IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food and Drug Administration (FDA) cleared direct-to-consumer (DTC) test for celiac disease genetics [...]
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
14/05/2025
BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today [...]
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
14/05/2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
3Daughters Selects Connect Labs by Wexford - Baltimore for New Corporate Headquarters
14/05/2025
Access to Wexford Knowledge Community Platform Supports Creation of a Women’s Health Science Hub Presence within UMB BioPark Ecosystem and Provides Critical Connections for Growth BALTIMORE, May 14, 2025 (GLOBE NEWSWIRE [...]
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
14/05/2025
Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation [...]
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
14/05/2025
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) ( CSE: BETR / OTCQB : BETRF / FRA: NPAU ), an emerging biotech company focused on the development of [...]
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection [...]
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
14/05/2025
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 [...]
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
14/05/2025
BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Yaqrit strengthens funding and regulatory capability ahead of clinical trials with board and senior management team appointments
14/05/2025
US economic strategist and hedge fund manager Ronen Israel appointed Board Director, deepening North American investment connectivity Amrik Shah, ScD, joins as Chief Biometrics Officer, enhancing prowess in clinical [...]
Noted Vaccine Researcher and Leader Kate O’Brien Awarded Sabin’s Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award
14/05/2025
WASHINGTON, May 13, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O’Brien, MD, MPH, for her research on the pneumococcal vaccine and [...]
Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier Trimestre
14/05/2025
INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier Trimestre La Société est en bonne voie pour obtenir l'autorisation de mise sur le marché au deuxième trimestre 2025 Les [...]
Nyxoah Reports First Quarter Financial and Operating Results
14/05/2025
REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final [...]
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting
14/05/2025
PRESS RELEASE Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting Milan, ITALY – 14 May 2025 – Genespire, a [...]
Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans le glaucome
14/05/2025
Communiqué de presse Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans le glaucome Plusieurs paramètres de l’humeur aqueuse stimulés par l’oxyde nitrique ont été statistiquement significatifs [...]
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
14/05/2025
Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; [...]

Pages